{Reference Type}: Case Reports
{Title}: A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment.
{Author}: Severi D;Palumbo G;Spina E;Iovino A;Nolano M;Manganelli F;Tozza S;
{Journal}: Neurol Sci
{Volume}: 44
{Issue}: 4
{Year}: Apr 2023
{Factor}: 3.83
{DOI}: 10.1007/s10072-022-06568-w
{Abstract}: <B>BACKGROUND: </B>Inotersen is an antisense oligonucleotide used to treat hereditary transthyretin amyloidosis (ATTRv). The most common drug-related adverse effects (AEs) include thrombocytopenia and glomerulonephritis. Hepatic damage is rare, but liver enzyme monitoring is mandatory.<BR><B>METHODS: </B>A 70-year-old man with ATTRv (Val30Met) treated with inotersen developed a severe increase of transaminases, with normal bilirubin and cholinesterase levels, that forced us to stop therapy. At the same time, other causes of acquired hepatitis were excluded, and the hypothesis of an inotersen-related hepatic toxicity was supported by the normalization of liver enzymes after 40 days from the drug interruption.<BR><B>CONCLUSIONS: </B>Our case showed that 1-year inotersen treatment can stabilize neurological impairment and even improve quality of life and suggests to carefully monitor liver enzymes in order to avoid an inotersen-related hepatic dysfunction.